Marco Agostini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1234302/publications.pdf

Version: 2024-02-01

140 3,507 32 52 papers citations h-index g-index

148 148 148 6628 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of $\hat{a}\in \infty$ Stealthy $\hat{a}\in \mathbb{N}$ Nanomaterials. Frontiers in Bioengineering and Biotechnology, 2020, 8, 166.	2.0	212
2	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. EBioMedicine, 2017, 20, 39-49.	2.7	170
3	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics, 2018, 50, 219-228.	9.4	139
4	Circulating Cell-Free DNA: A Promising Marker of Pathologic Tumor Response in Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy. Annals of Surgical Oncology, 2011, 18, 2461-2468.	0.7	114
5	Extracellular Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell Behavior?. Journal of Cellular Physiology, 2017, 232, 967-975.	2.0	108
6	An Advanced Lithiumâ€lon Sulfur Battery for High Energy Storage. Advanced Energy Materials, 2015, 5, 1500481.	10.2	97
7	Diagnostic and prognostic role of cellâ€free DNA testing for colorectal cancer patients. International Journal of Cancer, 2017, 140, 1888-1898.	2.3	96
8	Relationship Between Tumor and Plasma Levels of hTERT mRNA in Patients with Colorectal Cancer: Implications for Monitoring of Neoplastic Disease. Clinical Cancer Research, 2008, 14, 7444-7451.	3.2	82
9	Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers. Nanomedicine, 2015, 10, 1923-1940.	1.7	70
10	Circulating cell-free DNA: A promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomarkers, 2012, 11, 89-98.	0.8	68
11	Two PMS2 Mutations in a Turcot Syndrome Family with Small Bowel Cancers. American Journal of Gastroenterology, 2005, 100, 1886-1891.	0.2	65
12	Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics Journal, 2011, 11, 214-226.	0.9	63
13	Telomere-Specific Reverse Transcriptase (hTERT) and Cell-free RNA in Plasma as Predictors of Pathologic Tumor Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. Annals of Surgical Oncology, 2012, 19, 3089-3096.	0.7	61
14	Decellularized colorectal cancer matrix as bioactive microenvironment for in vitro 3D cancer research. Journal of Cellular Physiology, 2018, 233, 5937-5948.	2.0	61
15	Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma. Oncotarget, 2016, 7, 28647-28657.	0.8	61
16	Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAFV600E: A non-invasive tool panel for early detection of thyroid cancer. Biomedicine and Pharmacotherapy, 2013, 67, 723-730.	2.5	59
17	Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases. Nanoscale, 2017, 9, 14581-14591.	2.8	57
18	Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. British Journal of Cancer, 2013, 108, 278-284.	2.9	56

#	Article	IF	CITATIONS
19	NOTCH3 Signaling Regulates MUSASHI-1 Expression in Metastatic Colorectal Cancer Cells. Cancer Research, 2014, 74, 2106-2118.	0.4	56
20	A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenetics and Genomics, 2006, 16, 817-824.	0.7	54
21	Gene and MicroRNA Expression Are Predictive of Tumor Response in Rectal Adenocarcinoma Patients Treated With Preoperative Chemoradiotherapy. Journal of Cellular Physiology, 2017, 232, 426-435.	2.0	54
22	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget, 2014, 5, 6611-6619.	0.8	53
23	Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy. Journal of Controlled Release, 2017, 248, 144-152.	4.8	51
24	A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biology and Therapy, 2015, 16, 1160-1171.	1.5	49
25	An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget, 2015, 6, 32561-32574.	0.8	45
26	Patient-Derived Scaffolds of Colorectal Cancer Metastases as an Organotypic 3D Model of the Liver Metastatic Microenvironment. Cancers, 2020, 12, 364.	1.7	44
27	miRNAs in colon and rectal cancer: A consensus for their true clinical value. Clinica Chimica Acta, 2010, 411, 1181-1186.	0.5	40
28	Stability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with MSH2 intragenic deletion. European Journal of Human Genetics, 2006, 14, 63-68.	1.4	39
29	Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. International Journal of Biological Markers, 2015, 30, 136-141.	0.7	39
30	miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer. British Journal of Cancer, 2020, 122, 1354-1366.	2.9	38
31	Altered plasma levels of decanoic acid in colorectal cancer as a new diagnostic biomarker. Analytical and Bioanalytical Chemistry, 2016, 408, 6321-6328.	1.9	37
32	Integrated analysis of unclassified variants in mismatch repair genes. Genetics in Medicine, 2011, 13, 115-124.	1.1	34
33	Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L1189-L1199.	1.3	33
34	Recellularized Colorectal Cancer Patient-Derived Scaffolds as In Vitro Pre-Clinical 3D Model for Drug Screening. Cancers, 2020, 12, 681.	1.7	32
35	Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index. PLoS ONE, 2017, 12, e0169454.	1.1	32
36	Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. Hereditary Cancer in Clinical Practice, 2015, 13, 18.	0.6	31

#	Article	IF	Citations
37	Long non-coding RNA and extracellular matrix: the hidden players in cancer-stroma cross-talk. Non-coding RNA Research, 2018, 3, 174-177.	2.4	30
38	miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. Journal of Clinical Pathology, 2018, 71, 344-350.	1.0	29
39	Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer. Journal of Controlled Release, 2018, 281, 1-10.	4.8	29
40	High Risk of Rectal Cancer and of Metachronous Colorectal Cancer in Probands of Families Fulfilling the Amsterdam Criteria. Annals of Surgery, 2013, 257, 900-904.	2.1	27
41	Predictive response biomarkers in rectal cancer neoadjuvant treatment. Frontiers in Bioscience - Scholar, 2014, S6, 110-119.	0.8	26
42	Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer. Journal of Mass Spectrometry, 2006, 41, 1546-1553.	0.7	25
43	Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Research, 2006, 26, 3913-23.	0.5	24
44	The role of MYH gene in genetic predisposition to colorectal cancer: Another piece of the puzzle. Cancer Letters, 2008, 268, 308-313.	3.2	23
45	Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 360-367.	1.4	23
46	BTK inhibitors synergise with 5â€FU to treat drugâ€resistant <i>TP53</i> à€null colon cancers. Journal of Pathology, 2020, 250, 134-147.	2.1	23
47	Early-Age-at-Onset Colorectal Cancer and Microsatellite Instability as Markers of Hereditary Nonpolyposis Colorectal Cancer. Diseases of the Colon and Rectum, 2003, 46, 305-312.	0.7	22
48	Evaluation of Cell-free DNA in Urine as a Marker for Bladder Cancer Diagnosis. International Journal of Biological Markers, 2009, 24, 147-155.	0.7	22
49	A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors. Cancer Biomarkers, 2010, 6, 49-61.	0.8	22
50	Inflammation and Cancer: In Medio Stat Nano. Current Medicinal Chemistry, 2018, 25, 4208-4223.	1.2	22
51	Preclinical threeâ€dimensional colorectal cancer model: The next generation of in vitro drug efficacy evaluation. Journal of Cellular Physiology, 2019, 234, 181-191.	2.0	22
52	Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. Histopathology, 2012, 61, 247-256.	1.6	20
53	Tryptophan metabolism along the kynurenine and serotonin pathways reveals substantial differences in colon and rectal cancer. Metabolomics, 2017, 13, 1.	1.4	20
54	Nanovectors Design for Theranostic Applications in Colorectal Cancer. Journal of Oncology, 2019, 2019, 1-27.	0.6	20

#	Article	IF	Citations
55	Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are. Frontiers in Oncology, 2020, 10, 76.	1.3	20
56	Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. International Journal of Biological Markers, 2009, 24, 147-155.	0.7	20
57	Intrinsic and Extrinsic Modulators of the Epithelial to Mesenchymal Transition: Driving the Fate of Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 1122.	1.3	18
58	MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis. Current Drug Targets, 2015, 16, 383-392.	1.0	18
59	Proximal colon cancer in patients aged 51–60Âyears of age should be tested for microsatellites instability. A comment on the Revised Bethesda Guidelines. International Journal of Colorectal Disease, 2008, 23, 801-806.	1.0	17
60	Serum seleno-proteins status for colorectal cancer screening explored by data mining techniques - a multidisciplinary pilot study. Microchemical Journal, 2012, 105, 124-132.	2.3	17
61	Clinical Predictive Circulating Peptides in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Journal of Cellular Physiology, 2015, 230, 1822-1828.	2.0	17
62	Mass spectrometry in the pharmacokinetic studies of anticancer natural products. Mass Spectrometry Reviews, 2017, 36, 213-251.	2.8	17
63	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. Pathology Research and Practice, 2020, 216, 152907.	1.0	17
64	<i>MUTYH</i> c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in <i>MUTYH</i> â€Associated Polyposis. International Journal of Cancer, 2013, 132, 1060-1069.	2.3	16
65	miR-19a and SOCS-1 expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma. Journal of Clinical Pathology, 2016, 69, 415-421.	1.0	16
66	Latest Advances in Biomimetic Cell Membrane-Coated and Membrane-Derived Nanovectors for Biomedical Applications. Nanomaterials, 2022, 12, 1543.	1.9	16
67	Search of plasma markers for colorectal cancer by matrix-assisted laser desorption/ionization mass spectrometry. Journal of Mass Spectrometry, 2005, 40, 123-126.	0.7	15
68	Alterations of the Plasma Peptidome Profiling in Colorectal Cancer Progression. Journal of Cellular Physiology, 2016, 231, 915-925.	2.0	15
69	SerpinB3 upregulates the Cyclooxygenase-2 \mid \hat{l}^2 -Catenin positive loop in colorectal cancer. Oncotarget, 2017, 8, 15732-15743.	0.8	15
70	The role of mass spectrometry in studies of glycation processes and diabetes management. Mass Spectrometry Reviews, 2019, 38, 112-146.	2.8	15
71	Glutathione S-Transferase P1??lle105Val Polymorphism is Associated??with Haematological Toxicity in Elderly Rectal Cancer??Patients Receiving Preoperative Chemoradiotherapy. Drugs and Aging, 2008, 25, 531-539.	1.3	14
72	Experimental Evidence of the Presence of Bimolecular Caffeine/Catechin Complexes in Green Tea Extracts. Journal of Natural Products, 2018, 81, 2338-2347.	1.5	14

#	Article	IF	CITATIONS
73	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14
74	Integration of Flexibility from Distributed Energy Resources: Mapping the Innovative Italian Pilot Project UVAM. Energies, 2021, 14, 1910.	1.6	14
75	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Oncotarget, 2016, 7, 19781-19793.	0.8	14
76	MALDIâ€MS–NIST library approach for colorectal cancer diagnosis. Rapid Communications in Mass Spectrometry, 2009, 23, 2839-2845.	0.7	13
77	Rectum-Sparing Surgery May be Appropriate for Biallelic MutYH-Associated Polyposis. Diseases of the Colon and Rectum, 2010, 53, 1670-1675.	0.7	13
78	Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis. Molecular Biology Reports, 2012, 39, 9307-9310.	1.0	13
79	Decellularized normal and cancer tissues as tools for cancer research. Cancer Gene Therapy, 2022, 29, 879-888.	2.2	13
80	Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. Techniques in Coloproctology, 2013, 17, 79-87.	0.8	12
81	Biomarker Signature Discovery from Mass Spectrometry Data. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2014, 11, 766-772.	1.9	12
82	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. International Journal of Molecular Sciences, 2016, 17, 1482.	1.8	12
83	Neoadjuvant treatment for locally advanced rectal carcinoma. Critical Reviews in Oncology/Hematology, 2004, 52, 61-71.	2.0	11
84	PKH26 Staining Defines Distinct Subsets of Normal Human Colon Epithelial Cells at Different Maturation Stages. PLoS ONE, 2012, 7, e43379.	1.1	10
85	Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements. Analytical and Bioanalytical Chemistry, 2016, 408, 5369-5377.	1.9	10
86	Circulating Biomarkers for Response Prediction of Rectal Cancer to Neoadjuvant Chemoradiotherapy. Current Medicinal Chemistry, 2020, 27, 4274-4294.	1.2	10
87	Determining Therapeutic Approaches in the Elderly with Rectal Cancer. Drugs and Aging, 2007, 24, 781-790.	1.3	9
88	Medium chain fatty acids in intrauterine growth restricted and small for gestational age pregnancies. Metabolomics, 2017, 13, 1.	1.4	9
89	Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis. Digestive and Liver Disease, 2017, 49, 630-638.	0.4	8
90	Immunonutrition before esophagectomy: Impact on immune surveillance mechanisms. Tumor Biology, 2017, 39, 101042831772868.	0.8	8

#	Article	IF	Citations
91	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. Histopathology, 2017, 71, 1008-1011.	1.6	8
92	An investigation on the nature of the peptide atm/z 904, overexpressed in plasma of patients with colorectal cancer and familial adenomatous polyposis. Journal of Mass Spectrometry, 2007, 42, 1606-1612.	0.7	7
93	Matrix-Assisted Laser Desorption/Ionization, Nanostructure-Assisted Laser Desorption/Ionization and Carbon Nanohorns in the Detection of Antineoplastic Drugs. 1. The Cases of Irinotecan, Sunitinib and 6-Alpha-Hydroxy Paclitaxel. European Journal of Mass Spectrometry, 2014, 20, 445-459.	0.5	7
94	Peptide Patterns as Discriminating Biomarkers in Plasma of Patients With Familial Adenomatous Polyposis. Clinical Colorectal Cancer, 2016, 15, e75-e92.	1.0	7
95	Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts. Metabolites, 2018, 8, 91.	1.3	7
96	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer Cell International, 2018, 18, 131.	1.8	7
97	Leveraging Demand Flexibility by Exploiting Prosumer Response to Price Signals in Microgrids. Energies, 2020, 13, 3078.	1.6	7
98	Multiplexed Protein Signal Pathway Mapping Identifies Patients With Rectal Cancer That Responds to Neoadjuvant Treatment. Clinical Colorectal Cancer, 2012, 11, 268-274.	1.0	6
99	New Mass Spectrometric Approaches for the Quantitative Evaluation of Anticancer Drug Levels in Treated Patients. Therapeutic Drug Monitoring, 2019, 41, 1-10.	1.0	6
100	Tryptophan Catabolism and Response to Therapy in Locally Advanced Rectal Cancer (LARC) Patients. Frontiers in Oncology, 2020, 10, 583228.	1.3	6
101	Tumor Cells and the Extracellular Matrix Dictate the Pro-Tumoral Profile of Macrophages in CRC. Cancers, 2021, 13, 5199.	1.7	6
102	Factors affecting the treatment of multiple colorectal adenomas. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 207-213.	1.3	5
103	The development of a matrixâ€assisted laser desorption/ionization (MALDI)â€based analytical method for determination of irinotecan levels in human plasma: preliminary results. Journal of Mass Spectrometry, 2015, 50, 959-962.	0.7	5
104	Tryptophan Metabolism as Source of New Prognostic Biomarkers for FAP Patients. International Journal of Tryptophan Research, 2019, 12, 117864691989029.	1.0	5
105	A method for assessing plasma free fatty acids from C2 to C18 and its application for the early detection of colorectal cancer. Journal of Pharmaceutical and Biomedical Analysis, 2022, 215, 114762.	1.4	5
106	Genetic Heterogeneity of Variable Number Tandem Repeats in Thymidylate Synthase Gene in Colorectal Cancer Patients. International Journal of Biological Markers, 2004, 19, 332-336.	0.7	4
107	Long-term follow-up after endoscopic forceps biopsies for early stage duodenal carcinoid: case report and review of endoscopic treatments. Endoscopy, 2007, 39, E128-E128.	1.0	4
108	APCI1307K Mutations and Forkhead Box Gene (FOXO1A): Another Piece of an Interesting Correlation. International Journal of Biological Markers, 2012, 27, 13-19.	0.7	4

#	Article	IF	CITATIONS
109	A prognostic role for Nm23-H1 in laryngeal carcinoma treated with postoperative radiotherapy: an introductory investigation. European Archives of Oto-Rhino-Laryngology, 2013, 270, 197-203.	0.8	4
110	Field-Assisted Paper Spray Mass Spectrometry for the Quantitative Evaluation of Imatinib Levels in Plasma. European Journal of Mass Spectrometry, 2016, 22, 217-228.	0.5	4
111	Fieldâ€assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma. Journal of Mass Spectrometry, 2017, 52, 283-289.	0.7	4
112	Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers?. Diagnostics, 2021, 11, 253.	1.3	4
113	Diagnostic Devices for Circulating Biomarkers Detection and Quantification. Current Medicinal Chemistry, 2018, 25, 4304-4327.	1.2	4
114	Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients. International Journal of Biological Markers, 2004, 19, 332-336.	0.7	4
115	Optimization of Biomimetic, Leukocyte-Mimicking Nanovesicles for Drug Delivery Against Colorectal Cancer Using a Design of Experiment Approach. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	4
116	Clinical and molecular detection of inherited colorectal cancers in northeast Italy. Tumor Biology, 2012, 33, 857-864.	0.8	3
117	p65BTK targeting restores the apoptotic response to chemotherapy of p53-null drug-resistant colon cancer cells. European Journal of Cancer, 2016, 69, S140.	1.3	3
118	Ancillary services provision by aggregators and impact on distribution network operation. , 2019, , .		3
119	Voltammetric responses at modified electrodes and aggregation effects of two anticancer molecules: irinotecan and sunitinib. New Journal of Chemistry, 2020, 44, 18233-18241.	1.4	3
120	MASS SPECTROMETRY FOR A HOLISTIC VIEW OF NATURAL EXTRACTS OF PHYTOTHERAPEUTIC INTEREST. Mass Spectrometry Reviews, 2020, 39, 553-573.	2.8	3
121	Mass spectrometry in the study of molecular complexes between 5â€fluorouracil and catechins. Journal of Mass Spectrometry, 2021, 56, e4682.	0.7	3
122	Nanodelivery Systems Face Challenges and Limitations in Bone Diseases Management. Advanced Therapeutics, 2021, 4, 2100152.	1.6	3
123	A rhabdomyosarcoma hydrogel model to unveil cell-extracellular matrix interactions. Biomaterials Science, 2021, 10, 124-137.	2.6	3
124	An investigation on [5 fluorouracil and epigallocatechin-3-gallate] complex activity on HT-29 cell death and its stability in gastrointestinal fluid. Oncotarget, 2022, 13, 476-489.	0.8	3
125	Reply to Jaskowski et al. European Journal of Human Genetics, 2007, 15, 141-142.	1.4	2
126	Evidence of noncovalent complexes in some natural extracts: Ceylon tea and mate extracts. Journal of Mass Spectrometry, 2020, 55, e4459.	0.7	2

#	Article	IF	CITATIONS
127	Role of mass spectrometry in the study of interactions between amylin and metal ions. Mass Spectrometry Reviews, 2021, , .	2.8	2
128	An electrospray ionization study on complexes of amylin with $Cu(II)$ and $Cu(I)$. Journal of Mass Spectrometry, 2021, 56, e4773.	0.7	1
129	Metachronous colorectal cancer have a similar microsatellite instability frequency but a lower infiltration of lymphomononuclear cells than primary lesions. Surgery, 2022, 171, 1605-1611.	1.0	1
130	P72 FOXO1A and plasma low molecular weight proteins determination: a promising diagnostic approach and biomarker for colorectal tumors. European Journal of Cancer, Supplement, 2007, 5, 19.	2.2	0
131	OC.06.4 INSULIN SIGNALING IN BARRETT'S ESOPHAGUS: IN VITRO AND IN PATIENTS STUDIES. Digestive and Liver Disease, 2013, 45, S69-S70.	0.4	0
132	Multivariate Analysis Approach to the Serum Peptide Profile of Morbidly Obese Patients. Disease Markers, 2013, 34, 269-278.	0.6	0
133	P.08.4: Prevention of Esophageal Adenocarcinoma in Barrett's Esophagus Patients: A Moderate Calorie-Protein Restriction Program (CARE-PRO). Digestive and Liver Disease, 2017, 49, e180.	0.4	0
134	OC.14.1 IS THE ADHERENCE TO WCRF/AICR RECOMMENDATIONS INVOLVED IN BARRETT'S ESOPHAGUS ONSET AND ITS PROGRESSION TO EAC? A RETROSPECTIVE ANALYSIS IN A HIGH-RISK POPULATION. Digestive and Liver Disease, 2018, 50, e103.	0.4	0
135	Concurrent control of MV and LV networks for ancillary services provision. , 2019, , .		0
136	PC.01.9 ESOPHAGEAL MICROBIOTA COMPOSITION ACROSS BARRETT'S ESOPHAGUS-DYSPLASIA-EAC SEQUENCE. Digestive and Liver Disease, 2019, 51, e75.	0.4	0
137	Patient-derived ECM-scaffolds of colorectal cancer and liver metastases as organotypic 3D model of liver metastatic colonization. Journal of Hepatology, 2020, 73, S642-S643.	1.8	0
138	Abstract LB-214: Identification of patients with adenomas or early- and late-stage colon carcinomas using nanoporous silica chips for protein profiling., 2010,,.		0
139	Multivariate analysis approach to the serum peptide profile of morbidly obese patients. Disease Markers, 2013, 34, 269-78.	0.6	0
140	Establishment of a human 3D pancreatic ductal adenocarcinoma model based on a patient-derived extracellular matrix scaffold. European Journal of Surgical Oncology, 2022, 48, e135.	0.5	0